HC Wainwright Reaffirms “Buy” Rating for Evaxion Biotech A/S (NASDAQ:EVAX)

Evaxion Biotech A/S (NASDAQ:EVAX)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $14.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 449.02% from the stock’s current price.

Separately, Lake Street Capital reduced their target price on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th.

Evaxion Biotech A/S Price Performance

Evaxion Biotech A/S stock opened at $2.55 on Thursday. The firm’s 50-day simple moving average is $3.78 and its 200 day simple moving average is $9.71. The firm has a market capitalization of $2.98 million, a PE ratio of -1.76 and a beta of -0.28. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. Evaxion Biotech A/S has a 52 week low of $2.22 and a 52 week high of $22.50.

Hedge Funds Weigh In On Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC bought a new position in Evaxion Biotech A/S (NASDAQ:EVAX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned approximately 2.98% of Evaxion Biotech A/S as of its most recent SEC filing. 11.04% of the stock is owned by institutional investors.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.